(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.
Ovid Therapeutics's earnings in 2026 is -$36,330,000.On average, 12 Wall Street analysts forecast OVID's earnings for 2026 to be -$33,163,593, with the lowest OVID earnings forecast at -$55,830,485, and the highest OVID earnings forecast at -$18,394,151. On average, 8 Wall Street analysts forecast OVID's earnings for 2027 to be -$38,946,036, with the lowest OVID earnings forecast at -$67,694,463, and the highest OVID earnings forecast at -$21,463,403.
In 2028, OVID is forecast to generate -$28,812,518 in earnings, with the lowest earnings forecast at -$34,894,053 and the highest earnings forecast at -$25,422,810.